Clinical genitourinary cancer最新文献

{"title":"Characteristics of Abdominal Fat Based on CT Measurements to Predict Early Recurrence After Initial Surgery of NMIBC in Stage Ta/T1","authors":"Nengfeng Yu ,&nbsp;Congcong Xu ,&nbsp;Yiwei Jiang ,&nbsp;Dekai Liu ,&nbsp;Lianghao Lin ,&nbsp;Gangfu Zheng ,&nbsp;Jiaqi Du ,&nbsp;Kefan Yang ,&nbsp;Qifeng Zhong ,&nbsp;Yicheng Chen ,&nbsp;Yichun Zheng","doi":"10.1016/j.clgc.2024.102199","DOIUrl":"10.1016/j.clgc.2024.102199","url":null,"abstract":"<div><h3>Introduction</h3><p>This study aimed to assess the predictive value of abdominal fat characteristics measured by computed tomography (CT) in identifying early recurrence within one year post-initial transurethral resection of bladder tumor (TURBT) in patients with nonmuscle-invasive bladder cancer (NMIBC). A predictive model integrating fat features and clinical factors was developed to guide individualized treatment.</p></div><div><h3>Materials and Methods</h3><p>A retrospective analysis of 203 NMIBC patients from two medical centers was conducted. Abdominal CT images were analyzed using 3D Slicer software. Spearman correlation, logistic regression, and the Lasso algorithm were employed for data analysis. Predictive efficacy was assessed using the area under the curve (AUC) of receiver operating characteristic (ROC) and decision curve analysis (DCA). Calibration was evaluated using the Hosmer-Lemeshow test.</p></div><div><h3>Results</h3><p>Significant differences in abdominal fat characteristics were found between the recurrence and nonrecurrence groups. All fat features positively correlated with body mass index (BMI), with bilateral perirenal fat thickness (PrFT) showing superior predictive performance. Multivariate logistic regression identified independent predictors of early recurrence, including tumor number, early perfusion chemotherapy, left and right PrFT, and visceral fat area (VFA) at umbilical and renal hilum levels. The Lasso-based model achieved an AUC of 0.904, outperforming existing models.</p></div><div><h3>Conclusion</h3><p>Abdominal fat characteristics, especially bilateral PrFT, strongly correlate with early recurrence in NMIBC. The Lasso-based model, integrating fat and clinical factors, offers superior predictive efficacy and could improve individualized treatment strategies.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102199"},"PeriodicalIF":2.3,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer","authors":"Jennifer Obasi ,&nbsp;Komal Sharma ,&nbsp;Navonil De Sarkar ,&nbsp;Emmanuel S. Antonarakis ,&nbsp;Deepak Kilari","doi":"10.1016/j.clgc.2024.102187","DOIUrl":"10.1016/j.clgc.2024.102187","url":null,"abstract":"<div><p></p><ul><li><span>•</span><span><p>PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.</p></span></li><li><span>•</span><span><p>A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.</p></span></li><li><span>•</span><span><p>In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.</p></span></li></ul></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102187"},"PeriodicalIF":2.3,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world Efficacy and Safety of Low-Dose Abiraterone With Food and Standard-Dose Abiraterone in De Novo Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Analysis","authors":"Tu Anh Do ,&nbsp;Phuong Mai Tran ,&nbsp;Trang Huyen Vu ,&nbsp;Hung Khac Tran ,&nbsp;Huong Quynh Nguyen ,&nbsp;Loi Dinh Nguyen ,&nbsp;Hong Thi Nguyen ,&nbsp;Chu Van Nguyen","doi":"10.1016/j.clgc.2024.102191","DOIUrl":"10.1016/j.clgc.2024.102191","url":null,"abstract":"<div><h3>Background</h3><p>The standard treatment for de novo metastatic hormone-sensitive prostate cancer (mHSPC) involves androgen deprivation therapy (ADT) combined with next-generation hormonal agents and/or docetaxel. While the standard dose (STD) of abiraterone is 1,000 mg administered while fasting, recent evidence suggests that a low dose (LOW) of 250 mg taken with a low-fat meal may achieve comparable pharmacokinetic outcomes.</p></div><div><h3>Objectives</h3><p>This study aimed to evaluate the failure-free survival (FFS) and safety of LOW and STD in de novo high-risk mHSPC patients.</p></div><div><h3>Materials and Methods</h3><p>We conducted a retrospective analysis of males with de novo high-risk mHSPC treated with ADT plus abiraterone (250 mg with a low-fat meal or 1000 mg fasting) at the Vietnam National Cancer Hospital from January 2019 to May 2024. The primary endpoint was FFS, assessed using Kaplan-Meier and multivariate Cox regression analyses.</p></div><div><h3>Results</h3><p>The study included 183 patients, with 91 in the LOW group and 92 in the STD group. The rates of patients who achieved undetectable PSA (PSA &lt; 0.2 ng/ml) were 52.7% in the LOW group and 47.8% in the STD group. The median time to undetectable PSA was 6.9 months in the LOW group and 6.4 months in the STD group. The median overall FFS was 28.1 months (95% CI: 21.1 to 35.0) in the LOW group and 25.4 months (95% CI: 15.5 to 35.3) in the STD group (<em>P</em> = .286). Multivariate analysis indicated that visceral metastases and detectable PSA (PSA ≥ 0.2 ng/ml) were significant negative predictors of FFS in both groups. The incidence of grade 3 and grade 4 adverse events was similar between the LOW group and the STD group.</p></div><div><h3>Conclusions</h3><p>The LOW group and STD group showed effectiveness and safety in de novo high-risk mHSPC. The use of low-dose abiraterone in de novo mHSPC can significantly reduce treatment costs.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102191"},"PeriodicalIF":2.3,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142121977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study","authors":"Giuseppe Fotia ,&nbsp;Calogero Saieva ,&nbsp;Richard Lee-Ying ,&nbsp;Anna Patrikidou ,&nbsp;Pier Vitale Nuzzo ,&nbsp;Elisa Zanardi ,&nbsp;Sabrina Rossetti ,&nbsp;Matthew Davidsohn ,&nbsp;Marc Eid ,&nbsp;Talal El Zarif ,&nbsp;Heather McClure ,&nbsp;Gian Paolo Spinelli ,&nbsp;Alessandra Damassi ,&nbsp;Veronica Murianni ,&nbsp;Charles Vauchier ,&nbsp;Thiago Martins Oliveira ,&nbsp;Andrea Malgeri ,&nbsp;Mikol Modesti ,&nbsp;Ricardo Pereira Mestre ,&nbsp;Loana Valenca ,&nbsp;Edoardo Francini","doi":"10.1016/j.clgc.2024.102185","DOIUrl":"10.1016/j.clgc.2024.102185","url":null,"abstract":"<div><h3>Background</h3><p>Managing metastatic castration-resistant prostate cancer (mCRPC) in men aged ≥ 75 is challenging due to limited data. Regardless of age, in real-world clinical practice, most mCRPC still derive from failure of androgen deprivation therapy (ADT) with or without docetaxel (D) for metastatic castration-sensitive prostate cancer (mCSPC). As abiraterone acetate plus prednisone (AA) and enzalutamide (Enza) are common first-line treatments for mCRPC. The impact of prior use of D for mCSPC on the efficacy and safety of AA or Enza in this older population remains unclear.</p></div><div><h3>Methods</h3><p>A cohort of patients aged ≥ 75 years starting AA or Enza as first-line therapy for mCRPC from January 2015 to April 2019 was identified from the registries of 10 institutions. Patients were categorized into 2 groups based on previous use of D for mCSPC. Primary endpoints were cancer-specific survival (CSS) from AA or Enza start, CSS from ADT onset, and safety. We used Kaplan–Meier method to estimate the endpoints distribution, including median values with 95% confidence intervals (95% CI).</p></div><div><h3>Results</h3><p>Of the 337 patients identified, 24 (7.1%) received ADT+D and 313 (92.9%) received ADT alone for mCSPC. Median follow-up from AA/Enza start was 18.8 months. Median CSS from ADT or AA/Enza was not significantly different between ADT+D and ADT alone cohorts (71.9 vs. 52.7 months, <em>P</em> = .97; 25.4 vs. 27.2 months, <em>P</em> = .89, respectively). No statistically significant difference in adverse events (AEs) of any grade rate (58.3% vs. 52.1%, respectively; <em>P</em> = .67) or grade ≥ 3 (12.5% vs. 15.7%, respectively; <em>P</em> = 1.0) was found between ADT+D and ADT alone cohorts.</p></div><div><h3>Conclusions</h3><p>Despite the innate limitations of a retrospective design and relatively small size of the ADT+D cohort, this analysis suggests that elderly men receiving AA or Enza as first-line therapy for mCRPC have similar survival outcomes and tolerability, regardless of previous D for mCSPC.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 5","pages":"Article 102185"},"PeriodicalIF":2.3,"publicationDate":"2024-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1558767324001563/pdfft?md5=788cd2a22697f7d97ca7f99170dadc4f&pid=1-s2.0-S1558767324001563-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer","authors":"Vivek Narayan ,&nbsp;Miraj Y. Patel ,&nbsp;Siguroli Teitsson ,&nbsp;Lisa Rosenblatt ,&nbsp;Xin Yin ,&nbsp;Irina Pivneva ,&nbsp;Sophie Gao ,&nbsp;Manasvi Sundar ,&nbsp;Keith A. Betts","doi":"10.1016/j.clgc.2024.102188","DOIUrl":"10.1016/j.clgc.2024.102188","url":null,"abstract":"<div><h3>Background</h3><p>There is limited real-world data regarding subsequent treatment utilization and clinical outcomes following initial androgen receptor pathway inhibitor (ARPI) exposure for the treatment of advanced prostate cancer. This study aimed to address this evidence gap.</p></div><div><h3>Methods</h3><p>Electronic health records during 01/01/2013-07/31/2022 from Flatiron Health were used to identify adults with mCRPC, who had prior exposure to ARPIs (irrespective of the setting) and ≥1 post-ARPI line of therapy (LOT) in the mCRPC setting (index therapy: the first eligible LOT in the mCRPC setting). Treatment patterns and survival outcomes following the initiation of index therapy were reported.</p></div><div><h3>Results</h3><p>Among 804 ARPI-experienced mCRPC patients, 459 patients (57.1%) received another ARPI as their index therapy and 192 (23.9%) received chemotherapy as their index therapy. In the overall population, median time on the index therapy and median time from index therapy to next therapy were 4.1 and 6.2 months, respectively. Median overall survival and radiographic progression-free survival from the initiation of index therapy were 15.1 and 7.0 months, respectively.</p></div><div><h3>Conclusions</h3><p>In this real-world analysis, more than half of patients attempted at least 1 additional ARPI in the mCRPC setting, despite prior treatment with ARPIs. The short treatment duration and survival time highlight the unmet need for additional, effective therapies that may improve clinical outcomes in this population.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102188"},"PeriodicalIF":2.3,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1558767324001599/pdfft?md5=f083c4da3f437fcaba69eeb9c690a0b9&pid=1-s2.0-S1558767324001599-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate","authors":"Haley Meyer ,&nbsp;Rajitha Sunkara ,&nbsp;Emily Rothmann ,&nbsp;Amar Shah ,&nbsp;Irbaz Riaz ,&nbsp;Kevin Dale Courtney ,&nbsp;Andrew J. Armstrong ,&nbsp;Andrea Lippucci ,&nbsp;Syed Arsalan Ahmed Naqvi ,&nbsp;Melissa L. Stanton ,&nbsp;Himisha Beltran ,&nbsp;Alan Haruo Bryce","doi":"10.1016/j.clgc.2024.102172","DOIUrl":"10.1016/j.clgc.2024.102172","url":null,"abstract":"<div><h3>Introduction</h3><p>Lurbinectedin is FDA approved for treatment of metastatic small cell lung cancer (SCLC) following progression on or after platinum-based chemotherapy. Prostatic small cell or neuroendocrine carcinoma (SC/NEPC) behaves like SCLC; however, no safety or efficacy data for lurbinectedin in SC/NEPC exists.</p></div><div><h3>Patients and methods</h3><p>All SC/NEPC patients treated with lurbinectedin across 4 academic oncology centers were identified. Baseline patient data and lurbinectedin outcomes including radiographic responses (complete response [CR], partial response [PR], stable disease [SD], progressive disease [PD]), progression free survival (PFS), overall survival (OS), and treatment-related adverse events (trAEs) were described. Clinical benefit rate (CBR) included CR, PR, or SD on imaging. Descriptive statistics were performed.</p></div><div><h3>Results</h3><p>At first lurbinectedin dose, all 18 patients had metastatic disease. Median age was 63.5 (Range: 53-84), number of prior systemic therapies was 4 (Range: 2-7), and lurbinectedin cycles completed was 5 (Range: 1-10). ADT was administered during lurbinectedin treatment in 9/18 patients. CBR was 9/16 (56%). The most common trAEs were fatigue and anemia. Median OS and PFS were 6.01 (0.23-16.69) and 3.35 (0.16-7.79) months.</p></div><div><h3>Conclusions</h3><p>Lurbinectedin showed modest but significant clinical benefit in some patients with SC/NEPC and demonstrated an acceptable toxicity profile with no hospitalizations from trAEs. SC/NEPC is an aggressive disease with a poor prognosis for which more treatment options are needed. Evidence for subsequent treatments after platinum-based chemotherapy is lacking. Lurbinectedin is an active treatment option for SC/NEPC; however, larger confirmatory studies are needed.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 5","pages":"Article 102172"},"PeriodicalIF":2.3,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142130021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of Intraoperative Frozen Section Examination of Surgical Resection Margins of the Penis in Penile Cancer","authors":"Karl H. Pang ,&nbsp;Mohammad Yunis ,&nbsp;Aiman Haider ,&nbsp;Alex Freeman ,&nbsp;Paul Hadway ,&nbsp;Raj Nigam ,&nbsp;Rowland Rees ,&nbsp;Asif Muneer ,&nbsp;Hussain M. Alnajjar","doi":"10.1016/j.clgc.2024.102189","DOIUrl":"10.1016/j.clgc.2024.102189","url":null,"abstract":"<div><h3>Introduction</h3><p>Frozen section examination (FSE) of the tumor resection margins is important during penile-preserving surgery (PPS) in penile cancer. The margin status will impact on how much penile or urethral tissue is excised. We aim to evaluate the outcomes of intraoperative FSE of resection margins in PPS.</p></div><div><h3>Patients and Methods</h3><p>A retrospective analysis of patients with penile squamous cell carcinoma (SCC) who underwent a FSE of resection margins between 2010 and 2022 was conducted. FSEs were compared with the final histopathological analysis and the Diagnostic Testing Accuracy (DTA): sensitivity, specificity, positive (PPV) and negative predictive values (NPV) were calculated.</p></div><div><h3>Results</h3><p>Overall, 137 FSE were performed. The median (IQR) age was 65 (53-75) years. 118 (86.1%) patients had negative FSE margins, 16 (11.7%) had positive FSE margins and 3 (2.2%) had equivocal (atypical cells) results. The sensitivity, specificity, PPV, NPV and diagnostic accuracy of penile FSE were 66.7%, 100%, 100%, 93.2% and 94% respectively. 18 patients underwent further resection in the same episode due to a positive or equivocal FSE and 12 (66.7%) achieved negative margins. Limitations include the retrospective nature of the study and lack of control arm to compare with.</p></div><div><h3>Conclusions</h3><p>Intraoperative FSE performed at our center for the assessment of penile SCC margins is 66.7% sensitive and 100% specific. FSE should be considered in PPS, as it's an essential and a reliable diagnostic tool in minimizing over-treatment.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 5","pages":"Article 102189"},"PeriodicalIF":2.3,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1558767324001605/pdfft?md5=e640323c2a0a00633a62331d420e165c&pid=1-s2.0-S1558767324001605-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"National Trends in PSA Cancer Screening With Parallel Investigation of Colorectal Cancer Screening: An Analysis of the CDC Behavioral Risk Factor Surveillance System From 2012 to 2022","authors":"Anh Nguyen ,&nbsp;John Fastenau ,&nbsp;Juhi Mehta ,&nbsp;Evan Kovac ,&nbsp;Robert E. Weiss","doi":"10.1016/j.clgc.2024.102178","DOIUrl":"10.1016/j.clgc.2024.102178","url":null,"abstract":"<div><h3>Introduction/Background</h3><p>From 2012 to 2022 there have been numerous revisions in the United States Preventative Task Force guidelines for prostate cancer screening, including advising against PSA testing to allowing shared-decision making for men aged 55 to 69. We sought to observe trends in PSA testing rates in relation to the changing guidelines. Conversely, colorectal cancer screening recommendations remained consistent for patients aged 50-75 and we sought to use this as a comparison to observe the effect of differing guidelines.</p></div><div><h3>Methods</h3><p>The Centers for Disease Control Behavioral Risk Factor Surveillance System is a national database of surveys on health-related behaviors and preventive medical services. We extracted responses from 2012 to 2022 regarding both prostate and colorectal cancer screening. Our primary variable of interest was prostate cancer screening while colorectal cancer screening served as a positive control.</p></div><div><h3>Results</h3><p>Prostate cancer screening decreased among respondents from 70.1% in 2012 to 59.7% in 2022. However, there was a significant rebound in prostate cancer screening prevalence in 2022. In contrast, colorectal cancer screening rates steadily increased from 70.7% in 2012 to 78% in 2022. The annual percentage of men who had received prostate cancer screening was statistically different year to year.</p></div><div><h3>Conclusions</h3><p>Trends in the rate of screening for prostate and colorectal cancer appeared to adapt to the updated recommendations. However, further investigation regarding lower income levels, minority groups, and uninsured men are essential to address the social and racial disparities seen in prostate cancer screening. Efforts to promote shared-decision making may improve effective cancer screening.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102178"},"PeriodicalIF":2.3,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1558767324001496/pdfft?md5=f44144ce608a094174732288f5ef8b98&pid=1-s2.0-S1558767324001496-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142147165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney","authors":"Giulia Claire Giudice ,&nbsp;Marco Maruzzo ,&nbsp;Elena Verzoni ,&nbsp;Giuseppe Procopio ,&nbsp;Davide Bimbatti ,&nbsp;Pierangela Sepe ,&nbsp;Francesca Maines ,&nbsp;Francesco Grillone ,&nbsp;Alessia Cavo ,&nbsp;Matteo Santoni ,&nbsp;Nadia Cordua ,&nbsp;Giovanna Pecoraro ,&nbsp;Veronica Prati ,&nbsp;Marilena Di Napoli ,&nbsp;Eli Ollari ,&nbsp;Giuseppe Caruso ,&nbsp;Nicola Simoni ,&nbsp;Davide Campobasso ,&nbsp;Sebastiano Buti","doi":"10.1016/j.clgc.2024.102186","DOIUrl":"10.1016/j.clgc.2024.102186","url":null,"abstract":"<div><h3>Introduction</h3><p>Rare genitourinary tumors are lacking of randomized and observational data. We aimed to describe the clinical characteristics and outcomes of patients with collecting duct carcinoma (CDC) through the Meet-URO 23/I-RARE database.</p></div><div><h3>Materials and Methods</h3><p>We performed a multicentric retrospective-prospective study within the Meet-URO network, enrolling patients from March 2021 (retrospectively up from 2011) until March 2023. The primary objective was to describe the clinical characteristics of patients with CDC, the secondary objectives were to assess the oncological outcomes in terms of relapse-free survival (RFS), progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) to treatment.</p></div><div><h3>Results</h3><p>37 patients with CDC were enrolled. Four patients underwent only surgery, 33 received first-line systemic therapy. Median OS was 22.1 months (95% CI, 8.9-31.9). Median RFS for patients with localized disease at onset (n = 30) was 3.7 months (95% CI, 1.9-12.8), median PFS for first-line treatment was 3.3 months (95% CI, 2.7-9.9), with an ORR of 27%. Female sex and good performance status (PS) were associated with longer PFS (<em>P</em> = .072 and <em>P</em> &lt; .01, respectively) and OS (<em>P</em> = .030 and <em>P</em> = .141, respectively).</p></div><div><h3>Conclusions</h3><p>Patients with CDC had dismal prognosis, with scarce benefit from the available treatments. Female sex and good PS seemed to be associated with better prognosis.</p></div>","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 5","pages":"Article 102186"},"PeriodicalIF":2.3,"publicationDate":"2024-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1558767324001575/pdfft?md5=14fc6177345cb20a806b96fbf4d441a5&pid=1-s2.0-S1558767324001575-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142047680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic Prostate Cancer: Sequential or Combination Therapy?","authors":"Lorenzo Dottorini,&nbsp;Fausto Petrelli","doi":"10.1016/j.clgc.2024.102182","DOIUrl":"10.1016/j.clgc.2024.102182","url":null,"abstract":"","PeriodicalId":10380,"journal":{"name":"Clinical genitourinary cancer","volume":"22 6","pages":"Article 102182"},"PeriodicalIF":2.3,"publicationDate":"2024-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142006834","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}